 Clinical Trials as Topic
"Clinical Trials as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
| Descriptor ID |
D002986
|
| MeSH Number(s) |
E05.318.760.535 E05.337.250 N05.715.360.775.235 N06.850.520.450.535
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials as Topic".
This graph shows the total number of publications written about "Clinical Trials as Topic" by people in UAMS Profiles by year, and whether "Clinical Trials as Topic" was a major or minor topic of these publication.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 1 | 0 | 1 | | 2016 | 2 | 2 | 4 | | 2015 | 3 | 6 | 9 | | 2014 | 3 | 9 | 12 | | 2013 | 2 | 8 | 10 | | 2012 | 6 | 8 | 14 | | 2011 | 5 | 11 | 16 | | 2010 | 7 | 14 | 21 | | 2009 | 3 | 12 | 15 | | 2008 | 5 | 9 | 14 | | 2007 | 4 | 13 | 17 | | 2006 | 2 | 12 | 14 | | 2005 | 6 | 6 | 12 | | 2004 | 2 | 8 | 10 | | 2003 | 1 | 8 | 9 | | 2002 | 2 | 10 | 12 | | 2001 | 0 | 3 | 3 | | 2000 | 1 | 5 | 6 | | 1999 | 1 | 1 | 2 | | 1998 | 0 | 2 | 2 | | 1997 | 1 | 2 | 3 | | 1996 | 0 | 2 | 2 | | 1995 | 1 | 3 | 4 | | 1994 | 0 | 1 | 1 | | 1993 | 0 | 1 | 1 | | 1992 | 0 | 1 | 1 | | 1991 | 0 | 1 | 1 | | 1990 | 1 | 1 | 2 | | 1989 | 0 | 3 | 3 | | 1988 | 0 | 3 | 3 | | 1987 | 0 | 1 | 1 | | 1986 | 0 | 2 | 2 | | 1985 | 0 | 3 | 3 | | 1983 | 0 | 2 | 2 | | 1980 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Clinical Trials as Topic" by people in Profiles over the past ten years.
-
Eisenstein EL, Nordo AH, Zozus MN. Using Medical Informatics to Improve Clinical Trial Operations. Stud Health Technol Inform. 2017; 234:93-97.
-
Sterne JA, Hernán MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016 Oct 12; 355:i4919.
-
Sarkar S, Raymick J, Imam S. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives. Int J Mol Sci. 2016 Jun 08; 17(6).
-
Murphy GS, Szokol JW, Avram MJ, Greenberg SB, Shear TD, Vender JS, Landry E. Consent for Anesthesia Clinical Trials on the Day of Surgery: Patient Attitudes and Perceptions. Anesthesiology. 2016 Jun; 124(6):1246-55.
-
Thanendrarajan S, Davies FE, Morgan GJ, Schinke C, Mathur P, Heuck CJ, Zangari M, Epstein J, Yaccoby S, Weinhold N, Barlogie B, van Rhee F. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going? Immunotherapy. 2016; 8(3):367-84.
-
Elliott JH, Grimshaw J, Altman R, Bero L, Goodman SN, Henry D, Macleod M, Tovey D, Tugwell P, White H, Sim I. Informatics: Make sense of health data. Nature. 2015 Nov 05; 527(7576):31-2.
-
Henry D, Fitzpatrick T. Liberating the data from clinical trials. BMJ. 2015 Sep 16; 351:h4601.
-
Pothineni NV, Deshmukh A, Padmanabhan D, Kovelamudi S, Patel NJ, Badheka AO, Mulpuru SK, Paydak H, Noseworthy PA. Complication rates of ventricular tachycardia ablation: Comparison of safety outcomes derived from administrative databases and clinical trials. Int J Cardiol. 2015 Dec 15; 201:529-31.
-
Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neurosci Biobehav Rev. 2015 Aug; 55:294-321.
-
Cilingiroglu M, Patel RA, Dean LS. Late breaking trials of 2014 in structural heart disease and peripheral arterial disease: Commentary covering ACC, EuroPCR, SCAI, TCT, VIVA, ESC, and AHA. Catheter Cardiovasc Interv. 2015 Jul; 86(1):80-4.
-
Lieber BA, Taylor B, Appelboom G, Prasad K, Bruce S, Yang A, Bruce E, Christophe B, Connolly ES. Meta-analysis of telemonitoring to improve HbA1c levels: promise for stroke survivors. J Clin Neurosci. 2015 May; 22(5):807-11.
-
Torok NJ, Dranoff JA, Schuppan D, Friedman SL. Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology. 2015 Aug; 62(2):627-34.
-
Blake DR, Spielberg F, Levy V, Lensing S, Wolff PA, Venkatasubramanian L, Acevedo N, Padian N, Chattopadhyay I, Gaydos CA. Could home sexually transmitted infection specimen collection with e-prescription be a cost-effective strategy for clinical trials and clinical care? Sex Transm Dis. 2015 Jan; 42(1):13-9.
-
Bhutani M, Landgren O, Usmani SZ. Multiple myeloma: is it time for biomarker-driven therapy? Am Soc Clin Oncol Educ Book. 2015; e493-503.
-
McClure EA, Campbell AN, Pavlicova M, Hu M, Winhusen T, Vandrey RG, Ruglass LM, Covey LS, Stitzer ML, Kyle TL, Nunes EV. Cigarette Smoking During Substance Use Disorder Treatment: Secondary Outcomes from a National Drug Abuse Treatment Clinical Trials Network study. J Subst Abuse Treat. 2015 Jun; 53:39-46.
-
Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014 Nov 13; 124(20):3043-51.
-
Tremmel JA, Patel RA, Bhatt DL, Cilingiroglu M, Pinto DS, Dean LS, Grines CL. Commentary on highlighted late breaking trials in interventional cardiology at ESC, VIVA, TCT, and AHA 2013. Catheter Cardiovasc Interv. 2015 Jan 01; 85(1):95-103.
-
Barta SK, Xue X, Wang D, Lee JY, Kaplan LD, Ribera JM, Oriol A, Spina M, Tirelli U, Boue F, Wilson WH, Wyen C, Dunleavy K, Noy A, Sparano JA. A new prognostic score for AIDS-related lymphomas in the rituximab-era. Haematologica. 2014 Nov; 99(11):1731-7.
-
Liu YC, Stone K, van Rhee F. Siltuximab for multicentric Castleman disease. Expert Rev Hematol. 2014 Oct; 7(5):545-57.
-
Moynihan R, Henry D, Moons KG. Using evidence to combat overdiagnosis and overtreatment: evaluating treatments, tests, and disease definitions in the time of too much. PLoS Med. 2014 Jul; 11(7):e1001655.
-
van Rhee F, Giralt S, Barlogie B. The future of autologous stem cell transplantation in myeloma. Blood. 2014 Jul 17; 124(3):328-33.
-
Tremmel JA, Patel RA, Bhatt DL, Cilingiroglu M, Pinto DS, Dean LS, Grines CL. Commentary on late breaking trials in interventional cardiology at ESC, VIVA, TCT, AHA (Fall 2012), and ACC 2013. Catheter Cardiovasc Interv. 2014 May 01; 83(6):936-43.
-
Cochran G, Stitzer M, Nunes EV, Hu MC, Campbell A. Clinically relevant characteristics associated with early treatment drug use versus abstinence. Addict Sci Clin Pract. 2014 Apr 04; 9:6.
-
Brown RA, Lau YC, Lip GY. Vernakalant hydrochloride to treat atrial fibrillation. Expert Opin Pharmacother. 2014 Apr; 15(6):865-72.
-
Hirahatake KM, Slavin JL, Maki KC, Adams SH. Associations between dairy foods, diabetes, and metabolic health: potential mechanisms and future directions. Metabolism. 2014 May; 63(5):618-27.
-
Stewart WC, Limtong AC, Magrath GN, Rembold JC, Nelson LA, Stewart JA. Lower limits of intraocular pressure in glaucoma clinical trials. J Glaucoma. 2014 Feb; 23(2):e105-7.
-
Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, Kaplan LD, Ribera JM, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Wilson WH, Wyen C, Oriol A, Navarro JT, Dunleavy K, Little RF, Ratner L, Garcia O, Morgades M, Remick SC, Noy A, Sparano JA. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013 Nov 07; 122(19):3251-62.
-
Wielage R, Bansal M, Wilson K, Klein R, Happich M. Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective. Spine (Phila Pa 1976). 2013 May 15; 38(11):936-46.
-
Hasin DS, Auriacombe M, Borges G, Bucholz K, Budney A, Crowley T, Grant BF, O'Brien C, Petry NM, Schuckit M, Wall MM. The DSM-5 field trials and reliability of alcohol use disorder. Am J Psychiatry. 2013 Apr; 170(4):442-3.
-
August KJ, Narendran A, Neville KA. Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions. Drugs. 2013 Apr; 73(5):439-61.
-
Solomkin JS, Ristagno RL, Das AF, Cone JB, Wilson SE, Rotstein OD, Murphy BS, Severin KS, Bruss JB. Source control review in clinical trials of anti-infective agents in complicated intra-abdominal infections. Clin Infect Dis. 2013 Jun; 56(12):1765-73.
-
Cilingiroglu M, Marmagkiolis K, Wholey MH. Carotid artery stenting update. Future Cardiol. 2013 Mar; 9(2):193-7.
-
Feld J, Barta SK, Schinke C, Braunschweig I, Zhou Y, Verma AK. Linked-in: design and efficacy of antibody drug conjugates in oncology. Oncotarget. 2013 Mar; 4(3):397-412.
-
Fouad MN, Lee JY, Catalano PJ, Vogt TM, Zafar SY, West DW, Simon C, Klabunde CN, Kahn KL, Weeks JC, Kiefe CI. Enrollment of patients with lung and colorectal cancers onto clinical trials. J Oncol Pract. 2013 Mar; 9(2):e40-7.
-
Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F, Barlogie B. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013 Mar 07; 121(10):1819-23.
-
Prior FW, Clark K, Commean P, Freymann J, Jaffe C, Kirby J, Moore S, Smith K, Tarbox L, Vendt B, Marquez G. TCIA: An information resource to enable open science. Conf Proc IEEE Eng Med Biol Soc. 2013; 2013:1282-5.
-
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012 Oct 16; 60(16):1581-98.
-
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. Eur Heart J. 2012 Oct; 33(20):2551-67.
-
Khan RZ, Badros A. Role of carfilzomib in the treatment of multiple myeloma. Expert Rev Hematol. 2012 Aug; 5(4):361-72.
-
Landgrebe M, Azevedo A, Baguley D, Bauer C, Cacace A, Coelho C, Dornhoffer J, Figueiredo R, Flor H, Hajak G, van de Heyning P, Hiller W, Khedr E, Kleinjung T, Koller M, Lainez JM, Londero A, Martin WH, Mennemeier M, Piccirillo J, De Ridder D, Rupprecht R, Searchfield G, Vanneste S, Zeman F, Langguth B. Methodological aspects of clinical trials in tinnitus: a proposal for an international standard. J Psychosom Res. 2012 Aug; 73(2):112-21.
-
Javid SH, Unger JM, Gralow JR, Moinpour CM, Wozniak AJ, Goodwin JW, Lara PN, Williams PA, Hutchins LF, Gotay CC, Albain KS. A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316). Oncologist. 2012; 17(9):1180-90.
-
Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC, Fenwick K, Kozarewa I, Gonzalez D, Lord CJ, Ashworth A, Davies FE, Morgan GJ. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood. 2012 Aug 02; 120(5):1077-86.
-
Thanendrarajan S, Kim Y, Schmidt-Wolf I. New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opin Biol Ther. 2012 May; 12(5):565-72.
-
Palevsky PM, Molitoris BA, Okusa MD, Levin A, Waikar SS, Wald R, Chertow GM, Murray PT, Parikh CR, Shaw AD, Go AS, Faubel SG, Kellum JA, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene T, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA. Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology. Clin J Am Soc Nephrol. 2012 May; 7(5):844-50.
-
Molitoris BA, Okusa MD, Palevsky PM, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene TH, Faubel SG, Kellum JA, Wald R, Chertow GM, Levin A, Waikar SS, Murray PT, Parikh CR, Shaw AD, Go AS, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA. Design of clinical trials in AKI: a report from an NIDDK workshop. Trials of patients with sepsis and in selected hospital settings. Clin J Am Soc Nephrol. 2012 May; 7(5):856-60.
-
Okusa MD, Molitoris BA, Palevsky PM, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Faubel S, Kellum JA, Wald R, Chertow GM, Levin A, Waikar SS, Murray PT, Parikh CR, Shaw AD, Go AS, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene TH, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA. Design of clinical trials in acute kidney injury: a report from an NIDDK workshop--prevention trials. Clin J Am Soc Nephrol. 2012 May; 7(5):851-5.
-
Thompson ME, Jenkins J, Smucker A, Smithwick S, Groopman D, Pastore LM. Acupuncturist perceptions of serving as a clinical trial practitioner. Complement Ther Med. 2012 Aug; 20(4):183-9.
-
Zorn KK. PARP inhibition in epithelial ovarian cancer: high hopes undergo a reality check. Oncology (Williston Park). 2012 Feb; 26(2):128-36.
-
Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, Morgan G, Sonneveld P, Spencer A, Andersen KC, Facon T, Stewart KA, Einsele H, Mateos MV, Wijermans P, Waage A, Beksac M, Richardson PG, Hulin C, Niesvizky R, Lokhorst H, Landgren O, Bergsagel PL, Orlowski R, Hinke A, Cavo M, Attal M. IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012 Mar 29; 119(13):3003-15.
-
Rettiganti M, Nagaraja HN. Power analyses for negative binomial models with application to multiple sclerosis clinical trials. J Biopharm Stat. 2012; 22(2):237-59.
-
Barta SK, Lee JY, Kaplan LD, Noy A, Sparano JA. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer. 2012 Aug 15; 118(16):3977-83.
-
Saldaña SN, Hooper DK, Froehlich TE, Campbell KM, Prows CA, Sadhasivam S, Nick TG, Seid M, Vinks AA, Glauser TA. Characteristics of successful recruitment in prospective pediatric pharmacogenetic studies. Clin Ther. 2011 Dec; 33(12):2072-81.
-
Owens SM, Atchley WT, Hambuchen MD, Peterson EC, Gentry WB. Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction. CNS Neurol Disord Drug Targets. 2011 Dec; 10(8):892-8.
-
Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM, Coy NN, Cook G, Russell NH, Rudin C, Roddie H, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012 Jan 05; 119(1):7-15.
-
Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, Campbell TB, Eisenach KD, Hafner R, Lennox JL, Makhene M, Swindells S, Villarino ME, Weiner M, Benson C, Burman W. CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med. 2011 Oct 15; 184(8):972-9.
-
Carroll KM, Ball SA, Jackson R, Martino S, Petry NM, Stitzer ML, Wells EA, Weiss RD. Ten take home lessons from the first 10 years of the CTN and 10 recommendations for the future. Am J Drug Alcohol Abuse. 2011 Sep; 37(5):275-82.
-
Wong HK, Mishra A, Hake T, Porcu P. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol. 2011 Oct; 155(2):150-66.
-
Suva LJ, Brander BE, Makhoul I. Update on bone-modifying agents in metastatic breast cancer. Nat Rev Endocrinol. 2011 May 24; 7(7):380-1.
-
Prisciandaro JJ, Rembold J, Brown DG, Brady KT, Tolliver BK. Predictors of clinical trial dropout in individuals with co-occurring bipolar disorder and alcohol dependence. Drug Alcohol Depend. 2011 Nov 01; 118(2-3):493-6.
-
Uretsky BF. Letter by Uretsky regarding article, "Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the synergy between percutaneous coronary intervention with TAXUS and cardiac surgery (SYNTAX) trial". Circulation. 2011 Apr 05; 123(13):e398; author reply e399.
-
Neville KA, Becker ML, Goldman JL, Kearns GL. Developmental pharmacogenomics. Paediatr Anaesth. 2011 Mar; 21(3):255-65.
-
Morales AE, Thrailkill KM. GAD-alum immunotherapy in Type 1 diabetes mellitus. Immunotherapy. 2011 Mar; 3(3):323-32.
-
Duarte-Rojo A, Heathcote EJ, Feld JJ. 'Easy to treat' genotypes were not created equal: can rapid virological response (RVR) level the playing field? J Hepatol. 2011 Aug; 55(2):466-73.
-
Singla S, Karam P, Deshmukh AJ, Mehta J, Paydak H. Review of contemporary antiarrhythmic drug therapy for maintenance of sinus rhythm in atrial fibrillation. J Cardiovasc Pharmacol Ther. 2012 Mar; 17(1):12-20.
-
Seely KA, Prather PL, James LP, Moran JH. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv. 2011 Feb; 11(1):36-51.
-
Martin L, Anguita A, Graf N, Tsiknakis M, Brochhausen M, Rüping S, Bucur A, Sfakianakis S, Sengstag T, Buffa F, Stenzhorn H. ACGT: advancing clinico-genomic trials on cancer - four years of experience. Stud Health Technol Inform. 2011; 169:734-8.
-
Nahm M, Shepherd J, Buzenberg A, Rostami R, Corcoran A, McCall J, Pietrobon R. Design and implementation of an institutional case report form library. Clin Trials. 2011 Feb; 8(1):94-102.
-
Scurlock AM, Jones SM. An update on immunotherapy for food allergy. Curr Opin Allergy Clin Immunol. 2010 Dec; 10(6):587-93.
-
Gerullis H, Ecke TH, Eimer C, Heuck CJ, Otto T. mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review. Minerva Urol Nefrol. 2010 Dec; 62(4):411-23.
-
Movsas B, Vikram B, Hauer-Jensen M, Moulder JE, Basch E, Brown SL, Kachnic LA, Dicker AP, Coleman CN, Okunieff P. Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators. Clin Cancer Res. 2011 Jan 15; 17(2):222-8.
-
Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev. 2010 Nov; 24 Suppl 1:S13-9.
-
Morgan G. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies. Blood Rev. 2010 Nov; 24 Suppl 1:S27-32.
-
Cole FS, Alleyne C, Barks JD, Boyle RJ, Carroll JL, Dokken D, Edwards WH, Georgieff M, Gregory K, Johnston MV, Kramer M, Mitchell C, Neu J, Pursley DM, Robinson W, Rowitch DH. NIH consensus development conference: Inhaled nitric oxide therapy for premature infants. NIH Consens State Sci Statements. 2010 Oct 29; 27(5):1-34.
-
Engelhardt M, Udi J, Kleber M, Spencer A, Rocci A, Knop S, Bruno B, Bringhen S, Pérez-Simón JA, Zweegman S, Driessen C, Patriarca F, Gramatzki M, Terpos E, Sezer O, Kropff M, Straka C, Johnsen HE, Waage A, Boegsted M, Lokhorst H, Hájek R, Morgan G, Boccadoro M, Ludwig H, Cavo M, Polliack A, Sonneveld P, Einsele H, Palumbo A. European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. Leuk Lymphoma. 2010 Nov; 51(11):2006-11.
-
Graham DY, Fischbach L. Sequential therapy for Helicobacter pylori infection: ethical considerations revisited. J Clin Gastroenterol. 2010 Aug; 44(7):523.
-
Gizinski AM, Fox DA, Sarkar S. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets. Best Pract Res Clin Rheumatol. 2010 Aug; 24(4):463-77.
-
Sano M, Egelko S, Ferris S, Kaye J, Hayes TL, Mundt JC, Donohue M, Walter S, Sun S, Sauceda-Cerda L. Pilot study to show the feasibility of a multicenter trial of home-based assessment of people over 75 years old. Alzheimer Dis Assoc Disord. 2010 Jul-Sep; 24(3):256-63.
-
Wu LT, Pan JJ, Blazer DG, Tai B, Stitzer ML, Woody GE. Using a latent variable approach to inform gender and racial/ethnic differences in cocaine dependence: a National Drug Abuse Treatment Clinical Trials Network study. J Subst Abuse Treat. 2010 Jun; 38 Suppl 1:S70-9.
-
Budney AJ, Vandrey RG, Stanger C. [Pharmacological and psychosocial interventions for cannabis use disorders]. Rev Bras Psiquiatr. 2010 May; 32 Suppl 1:S46-55.
-
Klein MA, Nahin RL, Messina MJ, Rader JI, Thompson LU, Badger TM, Dwyer JT, Kim YS, Pontzer CH, Starke-Reed PE, Weaver CM. Guidance from an NIH workshop on designing, implementing, and reporting clinical studies of soy interventions. J Nutr. 2010 Jun; 140(6):1192S-1204S.
-
Penberthy L, Brown R, Puma F, Dahman B. Automated matching software for clinical trials eligibility: measuring efficiency and flexibility. Contemp Clin Trials. 2010 May; 31(3):207-17.
-
Dobesh PP, Swahn SM, Peterson EJ, Olsen KM. Statins in sepsis. J Pharm Pract. 2010 Feb; 23(1):38-49.
-
Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol. 2010 Mar 01; 28(7):1209-14.
-
Ludwig H, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San Miguel J, Shpilberg O, Sondergeld P, Sonneveld P, Zweegman S. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist. 2010; 15(1):6-25.
-
Kantorovich V, Pacak K. Pheochromocytoma and paraganglioma. Prog Brain Res. 2010; 182:343-73.
-
Stenzhorn H, Weiler G, Brochhausen M, Schera F, Kritsotakis V, Tsiknakis M, Kiefer S, Graf N. The ObTiMA system - ontology-based managing of clinical trials. Stud Health Technol Inform. 2010; 160(Pt 2):1090-4.
-
Rhodes C, Moore S, Clark K, Maffitt D, Perry J, Handzel T, Prior F. Regulatory compliance requirements for an open source electronic image trial management system. Conf Proc IEEE Eng Med Biol Soc. 2010; 2010:3475-8.
-
Warmack TS, Estes MA, Heldenbrand S, Franks AM. Beta-adrenergic antagonists in hypertension: a review of the evidence. Ann Pharmacother. 2009 Dec; 43(12):2031-43.
-
Carter LP, Stitzer ML, Henningfield JE, O'Connor RJ, Cummings KM, Hatsukami DK. Abuse liability assessment of tobacco products including potential reduced exposure products. Cancer Epidemiol Biomarkers Prev. 2009 Dec; 18(12):3241-62.
-
Torralba KD, Khan NA, Quismorio FP. Clinical trials and public trust: the geographical shift to the Asia-Pacific region. Int J Rheum Dis. 2009 Sep; 12(3):186-91.
-
Choi JY, Barlow WE, Albain KS, Hong CC, Blanco JG, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hayes DF, Ambrosone CB. Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin Cancer Res. 2009 Aug 15; 15(16):5258-66.
-
Ravina B, Swearingen C, Elm J, Kamp C, Kieburtz K, Kim SY. Long term understanding of study information in research participants with Parkinson's disease. Parkinsonism Relat Disord. 2010 Jan; 16(1):60-3.
-
Usmani SZ, Bona R, Li Z. 17 AAG for HSP90 inhibition in cancer--from bench to bedside. Curr Mol Med. 2009 Jun; 9(5):654-64.
-
Nair B, Shaughnessy JD, Zhou Y, Astrid-Cartron M, Qu P, van Rhee F, Anaissie E, Alsayed Y, Waheed S, Hollmig K, Szymonifka J, Petty N, Hoering A, Barlogie B. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. Blood. 2009 Jun 25; 113(26):6572-5.
-
Lin L, Lee JY, Kaplan LD, Dezube BJ, Noy A, Krown SE, Levine AM, Yu Y, Hayward GS, Ambinder RF. Effects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in blood. J Clin Oncol. 2009 May 20; 27(15):2496-502.
-
Muldrew KM, Franks AM. Succinobucol: review of the metabolic, antiplatelet and cardiovascular effects. Expert Opin Investig Drugs. 2009 Apr; 18(4):531-9.
-
Rostami R, Nahm M, Pieper CF. What can we learn from a decade of database audits? The Duke Clinical Research Institute experience, 1997--2006. Clin Trials. 2009 Apr; 6(2):141-50.
-
Ali TK, El-Remessy AB. Diabetic retinopathy: current management and experimental therapeutic targets. Pharmacotherapy. 2009 Feb; 29(2):182-92.
-
Sachdeva R, Prayaga S, Bansal D, Bagwe S, Hughes B, Molavi B, Romeo F, Mehta JL. Evolution of interventions for complex coronary lesions. Minerva Cardioangiol. 2009 Feb; 57(1):57-75.
-
Pan JJ, Nahm M, Wakim P, Cushing C, Poole L, Tai B, Pieper CF. A centralized informatics infrastructure for the National Institute on Drug Abuse Clinical Trials Network. Clin Trials. 2009 Feb; 6(1):67-75.
-
Kemp SF. Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options. BioDrugs. 2009; 23(3):155-63.
-
Krause MW, Raja R, Agarwal A, Silver MR, Scarlata D, Sciarra A, Kewalramani R. Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials. Drugs Aging. 2009; 26(8):665-75.
-
Nahm M, Zhang J. Operationalization of the UFuRT methodology for usability analysis in the clinical research data management domain. J Biomed Inform. 2009 Apr; 42(2):327-33.
-
Rudenko HC, Else M, Dearden C, Brito-Babapulle V, Jones C, Dexter T, Fenwick K, Mackay A, Ashworth A, Matutes E, Gonzalez D, Catovsky D, Morgan GJ. Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation. Leuk Lymphoma. 2008 Oct; 49(10):1879-86.
-
Johnson DC, Corthals S, Ramos C, Hoering A, Cocks K, Dickens NJ, Haessler J, Goldschmidt H, Child JA, Bell SE, Jackson G, Baris D, Rajkumar SV, Davies FE, Durie BG, Crowley J, Sonneveld P, Van Ness B, Morgan GJ. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood. 2008 Dec 15; 112(13):4924-34.
-
Rockett SR, Bryant JC, Morrow WR, Frazier EA, Fiser WP, McKamie WA, Johnson CE, Chipman CW, Imamura M, Jaquiss RD. Preliminary single center North American experience with the Berlin Heart pediatric EXCOR device. ASAIO J. 2008 Sep-Oct; 54(5):479-82.
-
Nahm ML, Pieper CF, Cunningham MM. Quantifying data quality for clinical trials using electronic data capture. PLoS One. 2008 Aug 25; 3(8):e3049.
-
Schneider MG, Swearingen CJ, Shulman LM, Ye J, Baumgarten M, Tilley BC. Minority enrollment in Parkinson's disease clinical trials. Parkinsonism Relat Disord. 2009 May; 15(4):258-62.
-
Barlogie B, Haessler J, Pineda-Roman M, Anaissie E, van Rhee F, Kiwan E, Steward D, Gurley J, Jenkins B, Crowley J. Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs. Cancer. 2008 Jun 15; 112(12):2720-5.
-
Callaghan RC, Taylor L, Moore BA, Jungerman FS, Vilela FA, Budney AJ. Recovery and URICA stage-of-change scores in three marijuana treatment studies. J Subst Abuse Treat. 2008 Dec; 35(4):419-26.
-
Burks AW, Laubach S, Jones SM. Oral tolerance, food allergy, and immunotherapy: implications for future treatment. J Allergy Clin Immunol. 2008 Jun; 121(6):1344-50.
-
Tsiknakis M, Brochhausen M, Nabrzyski J, Pucacki J, Sfakianakis SG, Potamias G, Desmedt C, Kafetzopoulos D. A semantic grid infrastructure enabling integrated access and analysis of multilevel biomedical data in support of postgenomic clinical trials on cancer. IEEE Trans Inf Technol Biomed. 2008 Mar; 12(2):205-17.
-
Palumbo A, Miguel JS, Sonneveld P, Moreau P, Drach J, Morgan G, Einsele H. Lenalidomide: a new therapy for multiple myeloma. Cancer Treat Rev. 2008 May; 34(3):283-91.
-
Arzoumanian V, Hoering A, Sawyer J, van Rhee F, Bailey C, Gurley J, Shaughnessy JD, Anaissie E, Crowley J, Barlogie B. Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia. 2008 Apr; 22(4):850-5.
-
Srikanth M, Davies FE, Morgan GJ. An update on drug combinations for treatment of myeloma. Expert Opin Investig Drugs. 2008 Jan; 17(1):1-12.
-
Smelson DA, Dixon L, Craig T, Remolina S, Batki SL, Niv N, Owen R. Pharmacological treatment of schizophrenia and co-occurring substance use disorders. CNS Drugs. 2008; 22(11):903-16.
-
Tsivgoulis G, Culp WC, Alexandrov AV. Ultrasound enhanced thrombolysis in acute arterial ischemia. Ultrasonics. 2008 Aug; 48(4):303-11.
-
Barlogie B, Anaissie E, van Rhee F, Pineda-Roman M, Zangari M, Shaughnessy J, Epstein J, Crowley J. The Arkansas approach to therapy of patients with multiple myeloma. Best Pract Res Clin Haematol. 2007 Dec; 20(4):761-81.
-
Ulrich SD, Bonutti PM, Seyler TM, Marker DR, Jones LC, Mont MA. Outcomes-based evaluations supporting computer-assisted surgery and minimally invasive surgery for total hip arthroplasty. Expert Rev Med Devices. 2007 Nov; 4(6):873-83.
-
Greist J, Mundt J, Jefferson J, Katzelnick D. Comments on "Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms?". J Clin Psychopharmacol. 2007 Oct; 27(5):535-7.
-
Bhutta AT. Ketamine: a controversial drug for neonates. Semin Perinatol. 2007 Oct; 31(5):303-8.
-
Bellone S, Pecorelli S, Cannon MJ, Santin AD. Advances in dendritic-cell-based therapeutic vaccines for cervical cancer. Expert Rev Anticancer Ther. 2007 Oct; 7(10):1473-86.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|